Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP10 | Q14694 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679945 | 0.90 | TDP1 (0.47) | MEN1KMT2APKMMAPTHTT | |
| SCHEMBL1679907 | 0.88 | L3MBTL1 (0.41) | MEN1KMT2APKMMAPTHTT | |
| SCHEMBL1679942 | 0.87 | POLB (0.41) | MEN1KMT2APKMMAPTHTT | |
| SCHEMBL1679895 | 0.86 | LMNA (0.40) | MEN1KMT2APKMMAPTL3MBTL1 | |
| SCHEMBL1679898 | 0.82 | TDP1 (0.47) | MEN1KMT2APKMMAPTL3MBTL1 | |
| SCHEMBL2333730 | 0.79 | HTT (0.59) | MEN1KMT2APKMMAPTTHRB | |
| SCHEMBL8263297 | 0.74 | MEN1 (0.55) | MEN1KMT2APKMMAPTTHRB | |
| SCHEMBL3533750 | 0.71 | PKM (0.49) | MEN1KMT2APKMMAPTTHRB | |
| SCHEMBL7719088 | 0.71 | PKM (0.49) | MEN1KMT2APKMMAPTTHRB | |
| SCHEMBL2331208 | 0.71 | ALDH1A1 (0.50) | MEN1KMT2APKMMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305649-B1 | METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF | NIPPON KAYAKU KK (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-8367833-B2 | Process for producing 6-aryloxyquinoline derivative and intermediate therefor | NIPPON KAYAKU CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2305649-A1 | METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF | Nippon Kayaku Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | FAR1, CYP4F11, WEE2 | MEN1 2109/4885KMT2A 902/4885PKM 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.